Medroxyprogesterone acetate
DB00603
Approved Indication
Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.
2
Targets
0
Resistance Mutations
2
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
Details
DrugBank ID
DB00603 ↗
Approval Date
1959-06-03
Molecular Weight
386.5244 g/mol
Drug Class
Other
ATC Codes
G03AC06, G03FA12, G03DA02, G03AA08, G03FB06, L02AB02
Synonyms
Medroxyacetate progesterone, Medroxyprogesterone acetate, Methylacetoxyprogesterone
PubChem
CID: 6279 ↗
ChEMBL
CHEMBL717 ↗
SMILES
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C
ADMET Profile
Computing properties…
Drug References (DrugBank)